Physician profile
Ruby Reyes
NPI 1093784050
$1,490.64
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,296 · 2020: $146 · 2021: $13.66 · 2022: $19.68 · 2023: $14.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $340.67 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $261.58 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $159.22 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $128.17 | 2019 | |
| Glaxosmithkline, LLC. | $128.15 | 2019-2023 | Trelegy Ellipta |
| Csl Behring | $99.85 | 2019 | |
| Pfizer INC. | $87.40 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.85 | 2019-2020 | |
| Shire North American Group INC | $43.92 | 2019 | |
| Optinose US, INC. | $41.00 | 2019 | |
| Alk-Abello, INC | $38.57 | 2019 | |
| Beigene USA, INC. | $19.68 | 2022 | |
| Greer Laboratories, INC. | $14.98 | 2019 | |
| Pharming Healthcare, INC. | $14.43 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.03 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $13.54 | 2019 | |
| Genentech USA, INC. | $13.07 | 2019 | |
| Bio Products Laboratory USA, INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.